Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Innate Immune Memory in Age-Related Macular Degeneration
Author Affiliations & Notes
  • Przemyslaw Mike Sapieha
    Universite de Montreal, Montreal, Quebec, Canada
    Unity Biotechnology, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Przemyslaw Mike Sapieha University of Montreal, Code P (Patent)
  • Footnotes
    Support  BrightFocus Foundation (M2022015I)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6134. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Przemyslaw Mike Sapieha; Innate Immune Memory in Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6134.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Diseases of the aging eye such dry and wet age-related macular degeneration (AMD) affect hundreds of millions of individuals worldwide and can be considered as the most prevalent neuroinflammatory diseases. Progression of AMD is influenced by persistent low- grade inflammation and a largely innate immune response. While significant effort has been invested to understand the genes that causes of AMD, variations and mutations in susceptibility genes only augment the chances of getting the disease but do not cause the disease. For example, the most highly linked mutations (such as complement factor H Y402H polymorphism) will increase chances of developing AMD by 4-fold, but will not necessarily trigger the disease. This suggests that other factors such as environment and lifestyle are key. We have recently identified a critical role for innate immune memory in AMD as a process linking environmental factors with epigenetic reprogramming of myeloid cells in the back of the eye. I will discuss how a past history of systemic infection or poor metabolic health reprograms myeloid cells to aggravate AMD and present novel potential therapeutic targets to counter these prevalent diseases of the aging eye based on these concepts.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×